Lawmakers expand the ‘Right to Try’ for New Hampshire’s terminally ill - New Hampshire Bulletin
New Hampshire expands the ‘Right to Try’ law, allowing terminally ill patients greater access to experimental treatments.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Pharmaceutical manufacturers and healthcare providers in New Hampshire. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate implementation as the law is effective upon passage.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Expanded access for terminally ill patients to experimental drugs not yet approved by the FDA.
Who it affects
Pharmaceutical manufacturers and healthcare providers in New Hampshire.
What you must do
Review and potentially adjust protocols for providing experimental treatments to eligible patients.
Deadline
Immediate implementation as the law is effective upon passage.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US FDA launches program to boost domestic drug manufacturing - reuters.com
- Sen. Pennycuick Legislation to Help Bring New Life-Saving Treatments and Devices to Market Quicker Passes Senate - pasenategop.com
- Committee Approves Pennycuick Measure to Modernize PA Pharmaceutical Licensing - pasenategop.com
- FDA launches PreCheck Pilot program to accelerate domestic drug manufacturing facility approvals - allsci.com
- Kratom and the Impact of 7-OH Reclassification - pharmtech.com